Cardiology Research and Practice最新文献

{"title":"Atorvastatin Inhibits Ferroptosis of H9C2 Cells by regulatingSMAD7/Hepcidin Expression to Improve Ischemia-Reperfusion Injury.","authors":"You Peng,&nbsp;Bin Liao,&nbsp;Yan Zhou,&nbsp;Wei Zeng,&nbsp;Zhi-Yu Zeng","doi":"10.1155/2022/3972829","DOIUrl":"https://doi.org/10.1155/2022/3972829","url":null,"abstract":"<p><strong>Background: </strong>Ferroptosis plays a key role in cardiomyopathy. Atorvastatin (ATV) has a protective effect on ischemia-reperfusion (I/R) cardiomyopathy. The purpose of this study is to elucidate the mechanism of ATV in I/R injury.</p><p><strong>Methods: </strong>H9C2 cells and cardiomyopathy rats were induced by hypoxia/reoxygenation (H/R) and I/R to construct <i>in vitro</i> and <i>in vivo</i> models. Cell viability was determined by CCK8. Cardiac histopathology was observed by HE staining. Transmission electron microscope (TEM) was used to observe the mitochondrial morphology. The reactive oxygen species (ROS) content in cells was analyzed by the biochemical method. ELISA was conducted to calculate the concentrations of total iron/Fe²⁺ and hepcidin. The expression of ferroptosis and SMAD pathway-related genes were detected by qPCR. Western blot was performed to detect the expression levels of ferroptosis and SMAD pathway-related proteins.</p><p><strong>Results: </strong>In H9C2 cells, ATV reversed the decline in cell viability, mitochondrial shrinkage, and ROS elevation induced by erastin or H/R. The concentration of total iron and Fe²⁺ in H/R-induced H9C2 cells increased, and the protein expression of FPN1 decreased. After ATV treatment, the concentration of total iron and Fe²⁺ decreased, and the protein expression of FPN1 increased. The expression of the SMAD7 gene in H/R-induced H9C2 cells decreased, and the expression of the hepcidin gene increased, which were reversed by ATV. When SMAD7 was knocked down, ATV treatment failed to produce the above effect. ATV also improved ferroptosis in I/R rat myocardium through the SMAD7/hepcidin pathway.</p><p><strong>Conclusions: </strong>ATV reversed the decline in H9C2 cell viability, mitochondrial shrinkage, and ROS elevation, and improved the myocardium ferroptosis through the SMAD7/hepcidin pathway in I/R rat.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":" ","pages":"3972829"},"PeriodicalIF":2.1,"publicationDate":"2022-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40498280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Significance of Percutaneous Coronary Intervention for First Acute Myocardial Infarction with Heart Failure: Five-Year Follow-Up Results.","authors":"Zichao Cheng,&nbsp;Yuchen Shi,&nbsp;Hongyu Peng,&nbsp;Donghui Zhao,&nbsp;Qian Fan,&nbsp;Jinghua Liu","doi":"10.1155/2022/5791295","DOIUrl":"https://doi.org/10.1155/2022/5791295","url":null,"abstract":"<p><strong>Objective: </strong>The study aimed to investigate the incidence and influencing factors of heart failure after 5 years of percutaneous coronary intervention (PCI) for first acute myocardial infarction.</p><p><strong>Methods: </strong>A total of 1235 patients, diagnosed as acute myocardial infarction and treated with PCI in Beijing Anzhen Hospital, Capital Medical University, from January 1, 2014, to December 31, 2014, were enrolled. Based on the exclusion criteria, 671 patients were followed up to obtain echocardiographic results 5 years after the onset of myocardial infarction (from January 1, 2019, to December 31, 2019). Of 671 patients, 62 were lost to follow-up. Finally, 609 patients were recruited in this study. According to the results of the echocardiographic examination, patients were divided into a heart failure group (<i>n</i> = 97) (LVEF < 50%) and a nonheart failure group (<i>n</i> = 512) (LVEF ≥ 50%). The clinical characteristics were compared between the two groups, and the influencing factors of heart failure after 5 years of PCI in patients with acute myocardial infarction were analyzed using logistic regression and receiver-operating characteristic (ROC) analyses.</p><p><strong>Results: </strong>Of 609 patients, 97 had heart failure within 5 years after PCI for first myocardial infarction, with an incidence of 15.9%. Multivariate regression analysis finally examined the predictors related to the occurrence of heart failure, including age (aOR, 1.008; 95% confidence interval (CI), 1.054-1.123; <i>P</i> ≤ 0.001), peak troponin I level (aOR, 1.020; 95% CI, 1.006-1.034; <i>P</i> = 0.004), left ventricular ejection fraction (LVEF) (during admission) (aOR, 0.908; 95% CI, 0.862-0.956; <i>P</i> ≤ 0.001), and left ventricular end-diastolic dimension (LVEDD) (at admission) (aOR, 1.136; 95% CI, 1.016-1.271; <i>P</i> = 0.025).</p><p><strong>Conclusion: </strong>In this study, the incidence of heart failure (LVEF < 50%) in patients with acute myocardial infarction who underwent PCI was 15.9% at a five-year follow up. Age, peak troponin I level, and LVEDD (at admission) were risk factors for heart failure, while LVEF (at admission) of patients during hospitalization was a protective factor for heart failure.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":" ","pages":"5791295"},"PeriodicalIF":2.1,"publicationDate":"2022-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649329/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40492163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Lycopene Supplementation on Some Cardiovascular Risk Factors and Markers of Endothelial Function in Iranian Patients with Ischemic Heart Failure: A Randomized Clinical Trial.","authors":"Bahareh Karimian,&nbsp;Azam Soleimani,&nbsp;Ghasem Mohammadsharifi,&nbsp;Kiyan Heshmat-Ghahdarijani,&nbsp;Laila Rejali,&nbsp;Davood Shafie,&nbsp;Atefeh Amerizadeh,&nbsp;Masoumeh Sadeghi","doi":"10.1155/2022/2610145","DOIUrl":"https://doi.org/10.1155/2022/2610145","url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to explore if supplementary lycopene tablets may help heart failure (HF) patients improve their lipid profile, BP, and the flow-mediated dilation (FMD) index for endothelial function.</p><p><strong>Methods: </strong>Fifty patients with ischemic HF with a reduced ejection fraction (HFrEF) were randomly assigned to one of two groups: the lycopene group which received 25 mg lycopene tablets once a day for 8 weeks and the control group which received placebo tablets containing starch once a day for 8 weeks.</p><p><strong>Results: </strong>Our results showed that after two months, the amount of triglyceride (TG) and FMD improved significantly compared to the control, TG decreased (219.27 vs. 234.24), and the mean of FMD increased (5.68 vs. 2.95). Other variables, including total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density cholesterol (HDL-C), systolic blood pressure (SBP), and diastolic blood pressure (DBP), showed no improvement. Also, only SBP and FMD showed intragroup improvement in the intervention group. In the intervention group, only SBP and FMD exhibited intragroup improvement.</p><p><strong>Conclusions: </strong>It can be concluded that supplementing with lycopene can enhance endothelial function and reduce the TG levels in ischemic HFrEF patients. However, it had no positive effect on BP, TC, LDL-C, or HDL-C. <i>Trial Registration</i>. This clinical trial was registered at the Iranian Registry of Clinical Trials with IRCT registration number: IRCT20210614051574N4.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":" ","pages":"2610145"},"PeriodicalIF":2.1,"publicationDate":"2022-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635958/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40456243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting Postoperative Troponin in Patients Undergoing Elective Hip or Knee Arthroplasty: A Comparison of Five Cardiac Risk Prediction Tools.","authors":"Merih T Tesfazghi,&nbsp;Anne R Bass,&nbsp;Noor Al-Hammadi,&nbsp;Scott C Woller,&nbsp;Scott M Stevens,&nbsp;Charles S Eby,&nbsp;Mitchell G Scott,&nbsp;Lindsey Snyder,&nbsp;Troy S Wildes,&nbsp;Brian F Gage","doi":"10.1155/2022/8244047","DOIUrl":"https://doi.org/10.1155/2022/8244047","url":null,"abstract":"Background Elderly patients undergoing hip or knee arthroplasty are at a risk for myocardial injury after noncardiac surgery (MINS). We evaluated the ability of five common cardiac risk scores, alone or combined with baseline high-sensitivity cardiac troponin I (hs-cTnI), in predicting MINS and postoperative day 2 (POD2) hs-cTnI levels in patients undergoing elective total hip or knee arthroplasty. Methods This study is ancillary to the Genetics-InFormatics Trial (GIFT) of Warfarin Therapy to Prevent Deep Venous Thrombosis, which enrolled patients 65 years and older undergoing elective total hip or knee arthroplasty. The five cardiac risk scores evaluated were the atherosclerotic cardiovascular disease calculator (ASCVD), the Framingham risk score (FRS), the American College of Surgeon's National Surgical Quality Improvement Program (ACS-NSQIP) calculator, the revised cardiac risk index (RCRI), and the reconstructed RCRI (R-RCRI). Results None of the scores predicted MINS in women. Among men, the ASCVD (C-statistic of 0.66; p=0.04), ACS-NSQIP (C-statistic of 0.69; p=0.01), and RCRI (C-statistic of 0.64; p=0.04) predicted MINS. Among all patients, spearman correlations (rs) of the risk scores with the POD2 hs-cTnI levels were 0.24, 0.20, 0.11, 0.11, and 0.08 for the ASCVD, Framingham, ACS-NSQIP, RCRI, and R-RCRI scores, respectively, with p values of <0.001, <0.001, <0.001, 0.006, and 0.025. Baseline hs-cTnI predicted MINS (C-statistics: 0.63 in women and 0.72 in men) and postoperative hs-cTnI (rs = 0.51, p=0.001). Conclusion In elderly patients undergoing elective hip or knee arthroplasty, several of the scores modestly predicted MINS in men and correlated with POD2 hs-cTnI.","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":" ","pages":"8244047"},"PeriodicalIF":2.1,"publicationDate":"2022-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40664748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum Zinc Ion Concentration Associated with Coronary Heart Disease: A Systematic Review and Meta-Analysis.","authors":"Heyu Meng,&nbsp;Jianjun Ruan,&nbsp;Yanqiu Chen,&nbsp;Zhaohan Yan,&nbsp;Xin Meng,&nbsp;Xiangdong Li,&nbsp;Jinsha Liu,&nbsp;Cuiying Mao,&nbsp;Ping Yang","doi":"10.1155/2022/4352484","DOIUrl":"https://doi.org/10.1155/2022/4352484","url":null,"abstract":"<p><strong>Aim: </strong>Coronary heart disease is a major cause of mortality in developed and developing countries. Changes in the trace element concentration in the human body are one of the main reasons for the transition of the human body from a healthy to a diseased state. In this meta-analysis, we have studied the relationship between the reduction in serum zinc ion concentration and coronary heart disease.</p><p><strong>Methods: </strong>We used PubMed and Cochrane (as of June 30, 2021) databases for the literature search. Per the requirements of this systematic review, case-control studies involving serum zinc ion concentration and coronary heart disease were searched, and the quality of the included studies was evaluated before the meta-analysis.</p><p><strong>Results: </strong>A total of 3,981 cases were found across seven articles. The standard mean deviation (SMD) of serum zinc ion concentration was -0.22 [-0.28, -0.15], <i>z</i> = 6.52, and <i>P</i> < 0.05 indicated that the difference was statistically significant. The forest plot results show that <i>I</i> ² = 34% < 50%, and the <i>Q</i> test showed <i>P</i>=0.17 > 0.1. These results suggest a lack of heterogeneity among the selected articles. Results from the funnel chart indicated that this study was free from publication bias.</p><p><strong>Conclusion: </strong>The results of this meta-analysis reveal that a decrease in serum zinc ion concentration is related to the occurrence of coronary heart disease. Clinically, monitoring the serum zinc ion levels is proven to be of great significance for patients with coronary heart disease.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":" ","pages":"4352484"},"PeriodicalIF":2.1,"publicationDate":"2022-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560831/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33516550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations between <i>β</i>-Blocker Therapy at Discharge and Long-Term Follow-Up Outcomes in Patients with Unstable Angina Pectoris.","authors":"Lei Liu,&nbsp;Xiaosong Ding,&nbsp;Hui Chen,&nbsp;Weiping Li,&nbsp;Hongwei Li","doi":"10.1155/2022/5287566","DOIUrl":"https://doi.org/10.1155/2022/5287566","url":null,"abstract":"<p><strong>Background: </strong>The effects of <i>β</i>-blockers in patients with unstable angina pectoris (UAP) are unclear. We tried to evaluate associations between <i>β</i>-blockers in UAP and long-term outcomes.</p><p><strong>Methods: </strong>We enrolled 5591 UAP patients and divided them into 2 groups based on <i>β</i>-blockers at discharge: 3790 did <i>β</i>-blockers and 1801 did not used them. Propensity score matching at 1 : 1 was performed to select 1786 patients from each group. The primary endpoint was major adverse cardiac and cerebral events (MACCE) during the long-term follow-up period.</p><p><strong>Results: </strong>67.8% of patients were on <i>β</i>-blockers at discharge; these patients were more likely to have CHD risk factors, lower ejection fraction, and severity of the coronary artery lesions. Over a median of 25.0 years, the incidence of MACCE was 25.5%. The risk was not significantly different between those on and those not on <i>β</i>-blocker treatment. The multivariate Cox regression analysis showed that no <i>β</i>-blocker use at discharge was not an independent risk factor for MACCE and sequence secondary endpoints. After propensity score matching, the results were similar.</p><p><strong>Conclusions: </strong><i>β</i>-blocker use was not associated with lower MACCE and other secondary composite endpoints in long-term outcomes. This result adds to the increasing body of evidence that the routine prescription of <i>β</i>-blockers might not be indicated in patients with UAP. Trial registration had retrospectively registered.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":" ","pages":"5287566"},"PeriodicalIF":2.1,"publicationDate":"2022-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33498194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Predictive Value of Epicardial Fat Tissue Volume in the Occurrence and Development of Atrial Fibrillation: A Systematic Review and Meta-Analysis.","authors":"Qiankun Fan,&nbsp;Yinge Zhan,&nbsp;Mingqi Zheng,&nbsp;Fangfang Ma,&nbsp;Lishuang Ji,&nbsp;Lei Zhang,&nbsp;Gang Liu","doi":"10.1155/2022/2090309","DOIUrl":"https://doi.org/10.1155/2022/2090309","url":null,"abstract":"<p><strong>Background: </strong>Atrial fibrillation (AF) is one of the most common arrhythmias in clinical practice. Although fat is currently considered to be a risk factor for AF and a pathogenic link between epicardial fat tissue (EFT) and AF has been speculated, there are currently few clinical studies and literature data domestically or abroad.</p><p><strong>Objective: </strong>This study conducted a meta-analysis of observational case series studies to verify the relationship between atrial fibrillation and EFT and to strengthen the predictive value of EFT in the occurrence, development, and postablative recurrence of AF.</p><p><strong>Methods: </strong>We conducted a systematic search of the literature in electronic databases until December 2021 and supplemented this through manual searches of individual studies, reviewed articles, and reference lists in conference proceedings. This study conducted a meta-analysis to compare the differences between different populations, such as healthy participants and AF patients, healthy subjects and AF subtype cases, and paroxysmal and persistent AF with AF recurrence and without AF recurrence after ablation.</p><p><strong>Results: </strong>Following the retrieval of 828 articles, only 22 articles were selected as research results. Accordingly, the meta-analysis results show that the volume of EFT in AF is greater than that in healthy subjects (MD = 39.34 ml, 95% CI = 27.11, 51.58); persistent AF is greater than paroxysmal AF (MD = 14.37 ml, 95% CI = 7.46, 21.27); and recurrence after ablation is greater than without recurrence (MD = 14.37 ml, 95% CI = 7.46, 21.27).</p><p><strong>Conclusion: </strong>The results of this study further confirm the connection between EFT and AF and that EFT has a certain predictive value for the occurrence and development of AF.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":" ","pages":"2090309"},"PeriodicalIF":2.1,"publicationDate":"2022-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537030/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33498195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Flow-Mediated Dilatation in the Assessment of Coronary Heart Disease: A Meta-Analysis.","authors":"Xiaoyong Xiao,&nbsp;Xian Li,&nbsp;Xiaohua Xiao,&nbsp;Jingjing Wang,&nbsp;Dehong Liu,&nbsp;Zhe Deng","doi":"10.1155/2022/7967324","DOIUrl":"https://doi.org/10.1155/2022/7967324","url":null,"abstract":"<p><p>Endothelial dysfunction may contribute to the increased morbidity and mortality associated with coronary heart disease (CHD). Flow-mediated dilatation (FMD) is the most popular noninvasive method for vascular endothelial function evaluation. This meta-analysis aimed to investigate the association between FMD and CHD. We searched the publications listed in the PubMed, Web of Science, Scopus, and Embase databases. Stata 14 software was used to analyze the data. Standardized mean difference (SMD) was used to calculate FMD levels, and the effect sizes were expressed with a 95% confidence interval (CI). I² statistics were used to evaluate statistical heterogeneity. In this meta-analysis, 9 studies enrolled a total number of 943 participants, including 534 (56.63%) patients with CHD and 409 controls (43.37%). We found that patients with CHD showed a significantly lower FMD than the controls (SMD -0.706%; 95% CI: -0.985, -0.427; <i>P</i>=0.001) with high heterogeneity. In addition, funnel plot analysis suggested asymmetry that could be evidence of publication bias. But sensitivity analyses show that there were no influential studies. This meta-analysis provides evidence that patients with CHD show a significantly lower FMD than controls and highlights the literature on FMD as a hallmark in CHD diseases.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":" ","pages":"7967324"},"PeriodicalIF":2.1,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33498197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitral Annular Plane Systolic Excursion (MAPSE) as a Predictor of Atrial Fibrillation Recurrence in Patients after Pulmonary Vein Isolation.","authors":"Jan Alatic,&nbsp;David Suran,&nbsp;Damijan Vokac,&nbsp;Franjo Husam Naji","doi":"10.1155/2022/2746304","DOIUrl":"https://doi.org/10.1155/2022/2746304","url":null,"abstract":"<p><strong>Introduction: </strong>Catheter ablation (CA) with pulmonary vein isolation (PVI) has become widely used in the past years for the treatment of atrial fibrillation (AF). Mitral annular plane systolic excursion (MAPSE) is the parameter that measures left ventricular longitudinal function, and it appears to be a good early marker of LV dysfunction. It is practically independent of poor image quality. The aim of our study was to analyse the role of echocardiographic variables, especially MAPSE in predicting the outcome of CA in patients with AF.</p><p><strong>Materials and methods: </strong>We prospectively included 40 patients with paroxysmal and persistent AF that were referred for CA. All patients underwent radiofrequency CA with PVI. Standard transthoracic two-dimensional echocardiography was conducted one day after CA. Demographic data and the patients' characteristics were noted. The endpoint of our study was to estimate the AF recurrence rate diagnosed by ECG within 6 months of the follow-up period.</p><p><strong>Results: </strong>40 patients, mainly male (67.5%) with an average age of 61.43 ± 8.96 years were included in our study. The majority of patients had paroxysmal AF prior to ablation (77.5%). The AF recurrence rate was 20% after 6 months of follow-up. Lateral MAPSE in the AF-free group was greater than those who relapsed (1.57 ± 0.24 vs. 1.31 ± 0.25; <i>p</i> = 0.012). Patients who remained AF-free after a 6-month follow-up period had a significantly smaller left ventricular volume index (LAVI) than those who relapsed (34.29 ± 6.91 ml/m² vs. 42.90 ± 8.43 ml/m²; <i>p</i> = 0.05). We found a significant reverse relationship between LAVI and MAPSE (<i>p</i> = 0.020).</p><p><strong>Conclusion: </strong>MAPSE and LAVI present risk factors for AF recurrence, specifically reduced MAPSE and larger LAVI, are related to AF recurrence after CA. In the future, MAPSE could play a significant role when predicting the CA outcome in patients with AF.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":" ","pages":"2746304"},"PeriodicalIF":2.1,"publicationDate":"2022-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532161/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33509495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BRD4 Silencing Protects Angiotensin II-Induced Cardiac Hypertrophy by Inhibiting TLR4/NF-<i>κ</i>B and Activating Nrf2-HO-1 Pathways.","authors":"Ming Fang,&nbsp;Jun Luo,&nbsp;Xi Zhu,&nbsp;Yingbiao Wu,&nbsp;Xinming Li","doi":"10.1155/2022/8372707","DOIUrl":"https://doi.org/10.1155/2022/8372707","url":null,"abstract":"<p><strong>Background: </strong>Heart failure is a critical health problem worldwide, and cardiac hypertrophy is an important characteristic of heart failure. Bromodomain-containing protein 4 (BRD4) is involved in various cellular processes, including cardiac hypertrophy. This study aimed to investigate the mechanism underlying the effects of BRD4 on cardiac hypertrophy.</p><p><strong>Methods: </strong>Rat myoblast H9c2 cells were treated with angiotensin II (Ang II) to increase the mRNA and protein expressions of BRD4. BRD4 was silenced by small interfering RNA (siRNA) in H9c2 cells. Proteins involved in Nrf2-HO-1 pathway were determined by Western blot.</p><p><strong>Results: </strong>Our data suggest that BRD4 silencing attenuated Ang II, increased the percentage of TUNEL + cells and caspase-3 activity, increased oxidative stress, and increased the expression and content of pro-inflammatory cytokines. Mechanistically, we found that BRD4 silencing enhanced the protein expressions of Nrf2 and HO-1 and inhibited the TLR4 and phosphorylation of NF-kappa B in Ang II-stimulated H9c2 cells. TLR4 overexpression attenuated cardioprotection against Ang II by BRD4 silencing, including cardiac hypertrophy, oxidative stress, and inflammatory cytokine production. Additionally, TLR4 overexpression attenuated an increase in Nrf2 and HO-1 proteins and decreased phosphorylated NF-kappa B in H9c2 cells.</p><p><strong>Conclusion: </strong>Our results speculate that the BRD4/TLR4 axis might be a promising strategy for treating cardiovascular diseases with cardiac hypertrophy, including HF.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":" ","pages":"8372707"},"PeriodicalIF":2.1,"publicationDate":"2022-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553838/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33515113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}